César Zepeda-Najar

César Zepeda-Najar

Auto-generated profile, based on publicly available information

César Zepeda-Najar

Surgical Oncology, Hospital Ángeles Tijuana, Tijuana, Baja California Norte, Mexico

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Melanoma Research
Verified
Journal Article
Closed access
PDF file
LLLeonardo A Lino-Silva
Leonardo A Lino-Silva
RSRosa A Salcedo-Hernández
Rosa A Salcedo-Hernández
LGLeticia García-Pérez
Leticia García-Pérez
AMAbelardo Meneses-García
Abelardo Meneses-García
CZCésar Zepeda-Najar
César Zepeda-Najar
Several studies have reported that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor clinical outcomes in several cancers, but this ratio has not been thoroughly studied in melanoma except in stage IV. This is the first study on NLR in melanoma stages I–III. This was a retrospective study of 742 melanoma patients. The NLR was classified into NLR<2 and a NLR≥2 on the basis of a receiver operating characteristic curve. Associations of NLR with clinicopathological characteristics and survival were examined. The median patient age was 57 years (range: 15–91; Q1=46, Q3=70), and the median Breslow’s thickness was 3.0 mm (range: 0.5–60; Q1=1.0, Q3=7). Clinical stage at presentation was as follows: (i) stage I in 27%; (ii) stage II in 33.2%; (iii) stage III in 36.5%; and (iv) stage IV in 3.3%. NLR≥2 was associated with lymph node metastasis (36.6 vs. 18.1%) and recurrence (28.2 vs. 22.1%). The 5-year overall survival (OS) was 63% for the NLR<2 group and 53% for the NLR≥2 group. Stage-by-stage analysis showed that the 5-year OS in the NLR≥2 group for stages I, II, III, and IV were 91, 60, 28, and 0%, respectively, whereas for the NLR<2 group the 5-year OS were 98, 68, 31, and 0%, respectively. Significant differences between NLR<2 and ≥2 occurred only in stage II (P=0.014). Univariate analysis showed that factors associated with decreased OS clinical stage were Breslow’s thickness, ulceration, male sex, and NLR≥2. In the multivariate analysis, all of these factors were predictors of decreased survival. The NLR appears to be an accurate prognostic marker for decreased OS in patients with melanoma, especially in clinical stage II. NLR≥2 correlated with lymph node metastasis and recurrence.

15 September 2018 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Open access
PDF file
LLLeonardo A Lino-Silva
Leonardo A Lino-Silva
CZCésar Zepeda-Najar
César Zepeda-Najar
RSRosa A. Salcedo-Hernández
Rosa A. Salcedo-Hernández
HMHéctor Martínez-Said
Héctor Martínez-Said
Acral lentiginous melanoma (ALM) is an aggressive variant of melanoma; the incidence, prevalence, and prognosis differ among populations. We analyzed clinicopathological features and survival in Hispanics, a population with high ALM prevalence. From 1144 patients with melanoma, we analyzed 715 ALMs and 429 non-ALMs from the National Referral Cancer Centre and compared survival. Of the ALM group, 62.8% were female; the median age was 58 years. The mean Breslow thickness was 3.56 ± 7.16 mm. ALM patients showed an estimated 5-year disease-specific survival (DSS) of 53.3%, 52.7%, and 40.8% for stage I, II, and III, respectively. For non-ALM patients, the DSS rates were 66%, 60.8%, and 48.4% for stage I, II, and III disease, respectively. Overall, the 1-, 3-, and 5-year DSS rates for patients with ALM were 85.1%, 59.4%, and 46.3%, respectively; for non-ALM patients, they were 81.3%, 64.8%, and 55.7%, respectively (P = .168). In the multivariate analysis, factors associated with decreased DSS were high Breslow thickness, recurrence, ulceration, male sex, and advanced stage. The 1-, 3-, and 5-year DSS rates of patients with ALM were not statistically different from those of non-ALM patients. In addition to known adverse prognostic factors, male sex was also associated with worse survival.

24 December 2018 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
LLLeonardo A Lino-Silva
Leonardo A Lino-Silva
JGJanet C. Guzmán‐López
Janet C. Guzmán‐López
CZCésar Zepeda‐Najar
César Zepeda‐Najar
RSRosa A. Salcedo‐Hernández
Rosa A. Salcedo‐Hernández
AMAbelardo Meneses‐García
Abelardo Meneses‐García

16 May 2018 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
LLLeonardo A Lino-Silva
Leonardo A Lino-Silva
PSPatricia Segales-Rojas
Patricia Segales-Rojas
EAEduardo Aguilar-Cruz
Eduardo Aguilar-Cruz
RSRosa A. Salcedo-Hernández
Rosa A. Salcedo-Hernández
CZCésar Zepeda-Najar
César Zepeda-Najar

5 July 2018 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
PLPatricia E. López-Correa
Patricia E. López-Correa
LLLeonardo A Lino-Silva
Leonardo A Lino-Silva
AGArmando Gamboa-Domínguez
Armando Gamboa-Domínguez
CZCésar Zepeda-Najar
César Zepeda-Najar
RSRosa A. Salcedo-Hernández
Rosa A. Salcedo-Hernández

8 January 2019 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
KGKarla J. González-Colunga
Karla J. González-Colunga
LLLeonardo A Lino-Silva
Leonardo A Lino-Silva
RSRosa A. Salcedo-Hernández
Rosa A. Salcedo-Hernández
ERErika B. Ruiz-García
Erika B. Ruiz-García
CZCésar Zepeda-Najar
César Zepeda-Najar